PE20050199A1 - Una forma de dosificacion que contiene pantoprazol como ingrediente activo - Google Patents

Una forma de dosificacion que contiene pantoprazol como ingrediente activo

Info

Publication number
PE20050199A1
PE20050199A1 PE2004000457A PE2004000457A PE20050199A1 PE 20050199 A1 PE20050199 A1 PE 20050199A1 PE 2004000457 A PE2004000457 A PE 2004000457A PE 2004000457 A PE2004000457 A PE 2004000457A PE 20050199 A1 PE20050199 A1 PE 20050199A1
Authority
PE
Peru
Prior art keywords
pantoprazole
dosage form
pvp
active ingredient
magnesium salt
Prior art date
Application number
PE2004000457A
Other languages
English (en)
Inventor
Rango Dietrich
Isabel Anstett-Klein
Hartmut Ney
Manfred Hartmann
Sabine Schafer-Preuss
Marc Schiller
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33436112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PE20050199A1 publication Critical patent/PE20050199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION DE LA SAL DE MAGNESIO DE PANTOPRAZOL EN FORMA DE TABLETA O PELLA QUE COMPRENDE (A) UNA CAPA ENTERICA SOLUBLE EN CONDICIONES NEUTRAS O ALCALINAS Y RESISTENTE AL JUGO GASTRICO FORMADA POR EUDRAGIT L 30 D Y CITRATO DE TRIETILO, (B) AL MENOS UNA CAPA DE SUBRECUBRIMIENTO INTERMEDIA INERTE SOLUBLE EN AGUA FORMADA POR HMPC, PVP 25 Y DIOXIDO DE TITANIO, ENTRE OTROS; (C) UN NUCLEO DE ENTRE 5 A 100 mg DE SAL DE MAGNESIO DE PANTOPRAZOL MEZCLADO CON UN LIGANTE, RELLENO Y UN COMPUESTO INORGANICO BASICO TALES COMO CARBONATO DE SODIO, PVP 90 (POVIDONA), Y ESTEARATO DE CALCIO. DICHA DOSIFICACION ES UTIL EN EL TRATAMIENTO DE ULCERA DUODENAL, SINDROME DE ZOLLINGER-ELLISON, ENTRE OTROS
PE2004000457A 2003-05-08 2004-05-05 Una forma de dosificacion que contiene pantoprazol como ingrediente activo PE20050199A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010328 2003-05-08
EP04001754 2004-01-28

Publications (1)

Publication Number Publication Date
PE20050199A1 true PE20050199A1 (es) 2005-03-26

Family

ID=33436112

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000457A PE20050199A1 (es) 2003-05-08 2004-05-05 Una forma de dosificacion que contiene pantoprazol como ingrediente activo

Country Status (27)

Country Link
US (2) US20060240100A1 (es)
EP (2) EP1624869B1 (es)
JP (2) JP4878284B2 (es)
KR (2) KR101237742B1 (es)
AR (1) AR044264A1 (es)
AU (2) AU2004237363B2 (es)
BR (2) BR122016006880B8 (es)
CA (1) CA2489140C (es)
CL (1) CL2004000983A1 (es)
CY (2) CY1113128T1 (es)
DK (2) DK2316454T3 (es)
EA (2) EA016824B1 (es)
ES (2) ES2390342T3 (es)
HK (1) HK1090546A1 (es)
HR (2) HRP20120754T1 (es)
IL (2) IL171365A (es)
MX (1) MXPA05000411A (es)
NO (1) NO337921B1 (es)
NZ (1) NZ543181A (es)
PE (1) PE20050199A1 (es)
PL (2) PL1624869T3 (es)
PT (2) PT1624869E (es)
RS (1) RS53443B (es)
SI (2) SI1624869T1 (es)
TW (1) TW200509992A (es)
WO (1) WO2004098594A2 (es)
ZA (1) ZA200508202B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
CA2565083C (en) 2004-05-07 2014-07-08 Altana Pharma Ag Novel pharmaceutical dosage form and manufacturing process
EP1895990A2 (en) * 2005-05-13 2008-03-12 Combino Pharm, S.L. Formulations containing pantoprazole free acid and its salts
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
WO2012010944A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Multiple unit tablet composition
KR101787481B1 (ko) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐
ITMI20111168A1 (it) * 2011-06-27 2012-12-28 Professional Dietetics Srl Composizioni farmaceutiche comprendenti idrossipropilmetilcellulosa e/o acido ialuronico e loro uso
US20150209432A1 (en) * 2012-07-26 2015-07-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3522889A4 (en) * 2016-10-06 2020-05-27 Jubilant Generics Limited PHARMACEUTICAL COMPOSITION OF PANTOPRAZOLE WITH DELAYED RELEASE AND METHOD FOR THE PRODUCTION THEREOF
WO2023214016A1 (en) * 2022-05-06 2023-11-09 Evonik Operations Gmbh Dosage form with drug release at ph 3 to 6 using double coating system with at least one release acceleration agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
IL85472A (en) 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
DE3901151A1 (de) 1989-01-17 1990-07-19 Hoechst Ag Stabile pharmazeutische zubereitungen von thienoimidazol-derivaten und deren orale anwendung als magensaeuresekretionshemmer
EP0474098B1 (en) 1990-08-30 1994-03-02 Senju Pharmaceutical Co., Ltd. Controlled drug release composition
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
WO1994024867A1 (en) * 1993-04-27 1994-11-10 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
UA41946C2 (uk) 1994-07-08 2001-10-15 Астра Актієболаг Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
JP3249914B2 (ja) * 1996-06-04 2002-01-28 清水食品株式会社 成型用焼結金型およびその形成方法
US6072024A (en) * 1997-03-21 2000-06-06 Mitsui Chemicals, Inc. Production process of cross-linked polyaspartic acid resin
WO1999027917A1 (de) * 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe
ATE500815T1 (de) 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
AU769038B2 (en) * 1998-05-15 2004-01-15 Warner-Lambert Company Llc Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
JP3274416B2 (ja) * 1998-05-29 2002-04-15 佐藤製薬株式会社 口腔内崩壊性粒状製剤
SI1105105T1 (sl) 1998-08-12 2006-08-31 Altana Pharma Ag Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE300285T1 (de) 1999-06-07 2005-08-15 Altana Pharma Ag Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
WO2002045692A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
JP2004514737A (ja) 2000-12-07 2004-05-20 アルタナ　ファルマ　アクチエンゲゼルシャフト 酸分解性活性成分を含有する迅速に崩壊する錠剤
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
CA2565083C (en) 2004-05-07 2014-07-08 Altana Pharma Ag Novel pharmaceutical dosage form and manufacturing process
JP4563077B2 (ja) 2004-05-28 2010-10-13 株式会社ロッテ キャンディ及びその製造方法

Also Published As

Publication number Publication date
JP2006525286A (ja) 2006-11-09
AU2004237363A1 (en) 2004-11-18
NO337921B1 (no) 2016-07-11
CY1113462T1 (el) 2016-06-22
SI2316454T1 (sl) 2013-01-31
BR122016006880B1 (pt) 2020-11-10
BRPI0410044B8 (pt) 2021-05-25
CA2489140A1 (en) 2004-11-18
EA200501697A1 (ru) 2006-06-30
KR101237742B1 (ko) 2013-02-26
WO2004098594A3 (en) 2004-12-09
PL1624869T3 (pl) 2012-11-30
ZA200508202B (en) 2006-12-27
RS53443B (en) 2014-12-31
EA027734B1 (ru) 2017-08-31
IL229510A (en) 2016-09-29
PL2316454T3 (pl) 2013-03-29
BR122016006880B8 (pt) 2021-05-25
JP2011126912A (ja) 2011-06-30
HRP20121005T1 (hr) 2013-01-31
EP1624869A2 (en) 2006-02-15
PT2316454E (pt) 2012-12-06
KR20110104124A (ko) 2011-09-21
US8703192B2 (en) 2014-04-22
ES2390342T3 (es) 2012-11-12
EP2316454B9 (en) 2013-01-02
TW200509992A (en) 2005-03-16
JP4878284B2 (ja) 2012-02-15
EP1624869B1 (en) 2012-07-04
DK2316454T3 (da) 2013-01-21
NO20055631L (no) 2005-11-29
US20090208571A1 (en) 2009-08-20
JP5162689B2 (ja) 2013-03-13
NZ543181A (en) 2009-10-30
IL229510A0 (en) 2013-12-31
US20060240100A1 (en) 2006-10-26
AR044264A1 (es) 2005-09-07
SI1624869T1 (sl) 2012-10-30
EA201101119A1 (ru) 2011-12-30
ES2396197T3 (es) 2013-02-19
AU2010200905A1 (en) 2010-04-01
EA016824B1 (ru) 2012-07-30
DK1624869T3 (da) 2012-10-01
PT1624869E (pt) 2012-09-18
AU2004237363B2 (en) 2009-12-10
RS20050818A (en) 2008-04-04
BRPI0410044A (pt) 2006-04-25
CL2004000983A1 (es) 2005-03-04
CY1113128T1 (el) 2016-04-13
WO2004098594A2 (en) 2004-11-18
MXPA05000411A (es) 2005-03-23
EP2316454B1 (en) 2012-09-26
IL171365A (en) 2014-08-31
HK1090546A1 (en) 2006-12-29
BRPI0410044B1 (pt) 2019-05-07
HRP20120754T1 (hr) 2012-11-30
CA2489140C (en) 2006-10-17
AU2010200905B2 (en) 2012-04-05
EP2316454A1 (en) 2011-05-04
KR20060010774A (ko) 2006-02-02

Similar Documents

Publication Publication Date Title
PE20050199A1 (es) Una forma de dosificacion que contiene pantoprazol como ingrediente activo
KR940701256A (ko) 판토프라졸 함유 약제의 경구 투여 형태
DK1246622T3 (da) Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse
JP5161071B2 (ja) 胃酸分泌
ES2168043A1 (es) Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
JP2006518751A5 (es)
DE60123384D1 (de) Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
ZA822995B (en) Slow release pharmaceutical composition
MY147180A (en) Pantoprazole multiparticulate formulations
CA2605839A1 (en) Stabilized composition of a proton pump inhibitor
JP2012153712A (ja) 胸やけの処置法
US9693962B2 (en) Dry-coated tablet
Thitiphuree et al. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy
PE20050150A1 (es) Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
US7981908B2 (en) Compositions and methods for inhibiting gastric acid secretion
US9233092B2 (en) Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
HRP20040596A2 (en) Compressed oral pharmaceutical dosage form, with an enteric coating, which contains an acid-labile benzimidazole compound
JP2003504338A5 (es)
RU2005122465A (ru) (-)-энантиомер тенатопразола и его применение в терапии
WO2013122554A1 (en) Pellet formulations comprising esomeprazole
KR102531045B1 (ko) 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제
Vivian et al. Pharmacologic strategies for treating gastroesophageal reflux disease
KR20170010510A (ko) 위장질환 치료용 삼중층 정제
CA2563162A1 (en) Dosage form containing pantoprazole as active ingredient
SI2032126T1 (sl) Formulacija z rabeprazolom

Legal Events

Date Code Title Description
FC Refusal